What is Noble Financial’s Forecast for UNCY Q2 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Noble Financial issued their Q2 2025 earnings per share (EPS) estimates for Unicycive Therapeutics in a report released on Thursday, May 15th. Noble Financial analyst R. Leboyer anticipates that the company will earn ($0.07) per share for the quarter. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.23) per share. Noble Financial also issued estimates for Unicycive Therapeutics’ Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at $0.13 EPS and FY2025 earnings at $0.04 EPS.

UNCY has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $7.50 price objective on shares of Unicycive Therapeutics in a report on Friday, April 11th. Guggenheim initiated coverage on Unicycive Therapeutics in a research note on Monday, April 21st. They issued a “buy” rating and a $6.00 price target for the company.

Unicycive Therapeutics Stock Performance

NASDAQ:UNCY opened at $0.60 on Monday. The company has a market cap of $72.38 million, a PE ratio of -0.62 and a beta of 2.14. Unicycive Therapeutics has a 52-week low of $0.20 and a 52-week high of $1.07. The stock has a 50-day simple moving average of $0.59 and a 200 day simple moving average of $0.61.

Unicycive Therapeutics (NASDAQ:UNCY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.09.

Institutional Investors Weigh In On Unicycive Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Nantahala Capital Management LLC grew its stake in Unicycive Therapeutics by 268.5% during the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company’s stock worth $8,253,000 after purchasing an additional 7,571,636 shares during the period. Geode Capital Management LLC boosted its stake in Unicycive Therapeutics by 30.3% during the fourth quarter. Geode Capital Management LLC now owns 524,487 shares of the company’s stock worth $417,000 after acquiring an additional 122,089 shares in the last quarter. XTX Topco Ltd boosted its stake in Unicycive Therapeutics by 142.2% during the fourth quarter. XTX Topco Ltd now owns 171,463 shares of the company’s stock worth $136,000 after acquiring an additional 100,679 shares in the last quarter. Vivo Capital LLC boosted its stake in Unicycive Therapeutics by 123.0% during the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company’s stock worth $7,918,000 after acquiring an additional 5,500,000 shares in the last quarter. Finally, Octagon Capital Advisors LP boosted its stake in Unicycive Therapeutics by 16.8% during the fourth quarter. Octagon Capital Advisors LP now owns 10,000,000 shares of the company’s stock worth $7,942,000 after acquiring an additional 1,441,000 shares in the last quarter. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.